# Malaria, Falciparum FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/malaria-falciparum

> 2 upcoming FDA catalysts in malaria, Falciparum: gsk3772701 600 mg (GSK) on Oct 2027 to Jan 2028 (topline data readout); gsk3772701 600 mg (GSK) on October 2027 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2027 to Jan 2028 | [Gsk3772701 600 mg topline data readout](https://sec-api.dev/pdufa/gsk3772701) | GSK | Malaria, Falciparum | scheduled | "NCT07545681 (A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-08 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07545681)) |
| October 2027 | [Gsk3772701 600 mg primary completion](https://sec-api.dev/pdufa/gsk3772701) | GSK | Malaria, Falciparum | scheduled | "NCT07545681 (A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-08 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07545681)) |

## Drugs

- [Gsk3772701 600 mg](https://sec-api.dev/pdufa/gsk3772701) (GSK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/malaria-falciparum.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Malaria, Falciparum FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/malaria-falciparum

```bibtex
@misc{secapidev_indications_malaria_falciparum_20261116,
  title        = {Malaria, Falciparum FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/malaria-falciparum}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_malaria_falciparum_20261116","title":"Malaria, Falciparum FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/malaria-falciparum","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
